Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Jevtana Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Prostate Cancer Agents: Jevtana (cabazitaxel) — Continuation of Therapy

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Jevtana (cabazitaxel) administered under the medical benefit for MassHealth members with metastatic castration-resistant prostate cancer. It establishes documentation requirements for members new to the plan, clinical criteria for authorization, and approval duration.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyProstate Cancer Agents: Jevtana (cabazitaxel) — Continuation of Therapy
    Policy CodePolicy N/A
    Change TypeMaterial clinical criteria update
    Effective DateJan 4, 202746d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing GnRH-analog therapy or prior bilateral orchiectomy for Jevtana continuation.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added a requirement that Jevtana be used with a gonadotropin-releasing hormone analog or that the member have undergone bilateral orchiectomy.

    The policy was reformatted and its references were updated.

    JevtanaCovered agent
    Medical

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Benefit channel
    Prior authUtilization management
    8 monthsApproval duration
    90 daysNew-plan threshold

    Coverage Criteria

    New-to-plan continuation documentation

    For members new to the plan, submit documentation of current treatment with the requested drug.

    New-to-plan documentation: The member's coverage effective date is less than or equal to 90 days, and medical records document that the member is currently receiving treatment with the requested drug.coverage effective date <= 90 days

    Treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this documentation requirement.

    Continuation therapy clinical criteria

    Authorization may be granted when all of the following criteria are met.

    Continuation authorization

    • Disease and prescriber: The member has metastatic castration-resistant prostate cancer and the prescriber is an oncologist.
    • Treatment regimen: Jevtana is prescribed at an appropriate dose and will be used in combination with prednisone.
    • Prior docetaxel outcome: The member had an inadequate response, meaning progression of cancer, or an adverse reaction to one docetaxel-containing regimen.one docetaxel-containing regimen
    • Androgen-deprivation treatment: The requested agent will be used in combination with a gonadotropin-releasing hormone (GnRH) analog, or the member has had a bilateral orchiectomy.one of two alternatives

    Continuation response

    For continuation requests, resubmission by the prescriber is treated as evidence of positive response to therapy.

    Resubmission response inference: A prescriber resubmission infers a positive response to therapy.

    For members new to the plan, medical records must document current treatment with the requested drug. Treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this documentation requirement.

    Jevtana Continuation Authorization

    Jevtana continuation authorization

    Authorization may be granted when all of the following criteria are met.

    Jevtana continuation criteria

    • Androgen-deprivation alternative: Jevtana will be used in combination with a gonadotropin-releasing hormone (GnRH) analog, or the member has had a bilateral orchiectomy.one of two alternatives

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Jevtana (cabazitaxel) requires prior authorization under the medical benefit.

    Documentation Required

    Clinical Authorization Criteria

    Authorization may be granted when all required clinical criteria are met for treatment of metastatic castration-resistant prostate cancer.

    • Diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
    • Prescriber is an oncologist
    • Appropriate dosing
    • Used in combination with prednisone
    • Inadequate response (progression of cancer) or adverse reaction to one docetaxel-containing regimen
    • Used in combination with a gonadotropin-releasing hormone (GnRH) analog, or the member has had a bilateral orchiectomy

    Therapeutic Background

    Jevtana (cabazitaxel) is used in combination with prednisone for patients with metastatic castration-resistant, or hormone-refractory, prostate cancer. The policy applies after treatment with a docetaxel-containing regimen and requires ongoing androgen-deprivation management through a GnRH analog or bilateral orchiectomy.

    Clinical Terminology

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyProstate Cancer Agents: Jevtana (cabazitaxel) — Continuation of Therapy
    Policy CodePolicy N/A
    Change TypeMaterial clinical criteria update
    Effective DateJan 4, 202746d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing GnRH-analog therapy or prior bilateral orchiectomy for Jevtana continuation.
    SourceLink
    On This Page
    Coverage CriteriaJevtana Continuation AuthorizationPrior Authorization and DocumentationTherapeutic BackgroundClinical Terminology
    Documentation Required

    New-to-Plan Treatment Records

    For members with a coverage effective date of 90 days or less, submit medical records documenting that the member is currently receiving treatment with the requested drug. This requirement does not apply when the product was obtained as samples or through a manufacturer's patient assistance program.

    • Coverage effective date: less than or equal to 90 days
    • Submit current-treatment medical records
    • Exclude treatment obtained through samples or manufacturer's patient assistance programs
    Denial Risk

    Failure to Meet Clinical Criteria

    Authorization may be denied when the requested treatment does not meet the clinical requirements. Documentation must support the diagnosis, oncology prescriber, appropriate dosing, required combination therapy, prior docetaxel-containing regimen response or intolerance, and the GnRH analog or bilateral orchiectomy requirement.

    • No diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
    • Prescriber is not an oncologist
    • Dosing is not appropriate
    • Requested agent is not used with prednisone
    • No inadequate response or adverse reaction to one docetaxel-containing regimen
    • Neither combination with a GnRH analog nor prior bilateral orchiectomy is documented